ClinicalTrials.gg
CompletedNCT02387801Updated Sep 18, 2019Results posted

A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis

A Phase 3 interventional study of Ixekizumab in Psoriasis, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-18.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.

Enrollment
20th of 22
12 · median 156
Started
2015
with 2 others
Phase 3
11 of 22
none open now
Registered
7th of 22
by date
Lead sponsor
16 of 22
Eli Lilly and Company

Among the 22 studies testing ixekizumab in Psoriasis, this one is the 20th largest by enrollment, is one of 3 that started in 2015, is one of 11 in phase 3, and was the 7th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ixekizumab

ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ixekizumab in Psoriasis, or all of them as a file.
02

Study summary

To detect onset of activity of ixekizumab in participants with moderate-to-severe plaque psoriasis and to document the same using sequential photographic images.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Present with chronic moderate-to-severe plaque psoriasis based on a confirmed (by a dermatologist) diagnosis of chronic plaque psoriasis for at least 6 months prior to baseline
  • Active psoriatic skin lesions of plaque psoriasis (Ps)
  • Are a candidate for phototherapy and/or systemic therapy
  • Men must agree to use a reliable method of or remain abstinent during the study and for at least 12 weeks after stopping treatment
  • Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment

Exclusion criteria

Exclusion Criteria:

  • Are unable to commit to the photography schedule for the duration of the study
  • Have participated in any study with interleukin 17 (IL-17) or (IL-23) antagonists, including ixekizumab
  • Serious disorder or illness other than psoriasis
  • Serious infection within the last 3 months
  • Breastfeeding or nursing (lactating) women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Ixekizumab Dosing Q2W

    160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q2W) every 2 weeks through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44.

    Drug: Ixekizumab

  • Experimental
    Ixekizumab Dosing Q4W

    160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q4W) every 4 weeks through week 44.

    Drug: Ixekizumab

Interventions

  • Administered SC

    Also known as: LY2439821

06

What researchers measure

Primary outcomes

  1. Time to at Least a 1 Point Improvement on the Patient's Global Assessment of Disease Severity (PatGA) Score

    The PatGA is a patient-administered single-item scale on which participants are asked to rank by selecting a number on a 0 to 5 Numeric Rating Score (NRS) the severity of their psoriasis "today" from 0 (Clear) = no psoriasis to 5 (Severe) = the worst their psoriasis has ever been.

    Time frame: Baseline through Week 12

Secondary outcomes

  1. Mean Change From Baseline on Itch Numeric Rating Scale (NRS) Score

    The Itch NRS is a patient-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from psoriasis (Ps) is indicated by circling the number that best describes the worst level of itching in the past 24 hours. Least Square Means (LS means) are from analysis of mixed-effects model for repeated measures (MMRM) and model includes treatment group, baseline value and timepoint.

    Time frame: Baseline, Week 12

  2. Mean Change From Baseline on the Dermatology Life Quality Index (DLQI)

    The DLQI is a simple, patient-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". For all questions, if unanswered the question is scored as "0". Totals range from 0 to 30 (less to more impairment). LS means are from analysis of MMRM and model includes treatment group, baseline value and timepoint.

    Time frame: Baseline, Week 12

  3. Mean Change From Baseline in Percent Body Surface Area (%BSA)

    The BSA is the percentage involvement of psoriasis on each participant's body surface on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand (including the palm, fingers, and thumb). The total BSA affected was the summation of individual regions affected. LS means are from analysis of MMRM and the model includes treatment group, baseline value, visit and treatment-by-visit interaction

    Time frame: Baseline, Week 12

  4. Mean Change From Baseline on the Psoriasis Area and Severity Index (PASI)

    The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in PASI scores compared to baseline. LS means are from analysis of MMRM and the model includes treatment group, baseline value, visit and treatment-by-visit interaction.

    Time frame: Baseline, Week 12

  5. Time to at Least a 2 Point Improvement on the PatGA Score

    The PatGA is a patient-administered single-item scale on which participants are asked to rank by selecting a number on a 0 to 5 NRS the severity of their psoriasis "today" from 0 (Clear) = no psoriasis to 5 (Severe) = the worst their psoriasis has ever been.

    Time frame: Baseline though Week 12

07

Results

Posted Oct 21, 2016

Participant flow

Induction Dosing Period (Weeks 0 up to 12), Maintenance Dosing Period (Weeks 12 up to 48), Minimum Post Treatment Follow-Up Period up to 12 weeks after last visit.

Induction Dosing Period
Participant flow — Induction Dosing Period
MilestoneIxekizumab Q2WIxekizumab Q4W
Started66
Completed66
Not completed00
Maintenance Dosing Period
Participant flow — Maintenance Dosing Period
MilestoneIxekizumab Q2WIxekizumab Q4W
Started012
Completed012
Not completed00
Post-Treatment Follow-up
Participant flow — Post-Treatment Follow-up
MilestoneIxekizumab Q2WIxekizumab Q4W
Started012
Completed012
Not completed00

Outcome measures

PrimaryTime to at Least a 1 Point Improvement on the Patient's Global Assessment of Disease Severity (PatGA) Score

The PatGA is a patient-administered single-item scale on which participants are asked to rank by selecting a number on a 0 to 5 Numeric Rating Score (NRS) the severity of their psoriasis "today" from 0 (Clear) = no psoriasis to 5 (Severe) = the worst their psoriasis has ever been.

Time frame:
Baseline through Week 12
Reported as:
Median · Days
Time to at Least a 1 Point Improvement on the Patient's Global Assessment of Disease Severity (PatGA) Score
DaysIxekizumab Q2WIxekizumab Q4W
Time to at Least a 1 Point Improvement on the Patient's Global Assessment of Disease Severity (PatGA) Score5.0 (2.0 to 5.0)6.0 (4.0 to 7.0)
SecondaryMean Change From Baseline on Itch Numeric Rating Scale (NRS) Score

The Itch NRS is a patient-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from psoriasis (Ps) is indicated by circling the number that best describes the worst level of itching in the past 24 hours. Least Square Means (LS means) are from analysis of mixed-effects model for repeated measures (MMRM) and model includes treatment group, baseline value and timepoint.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline on Itch Numeric Rating Scale (NRS) Score
units on a scaleIxekizumab Q2WIxekizumab Q4W
Mean Change From Baseline on Itch Numeric Rating Scale (NRS) Score-6.2 ± 0.53-6.6 ± 0.55
SecondaryMean Change From Baseline on the Dermatology Life Quality Index (DLQI)

The DLQI is a simple, patient-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". For all questions, if unanswered the question is scored as "0". Totals range from 0 to 30 (less to more impairment). LS means are from analysis of MMRM and model includes treatment group, baseline value and timepoint.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline on the Dermatology Life Quality Index (DLQI)
units on a scaleIxekizumab Q2WIxekizumab Q4W
Mean Change From Baseline on the Dermatology Life Quality Index (DLQI)-13.4 ± 1.56-14.3 ± 1.59
SecondaryMean Change From Baseline in Percent Body Surface Area (%BSA)

The BSA is the percentage involvement of psoriasis on each participant's body surface on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand (including the palm, fingers, and thumb). The total BSA affected was the summation of individual regions affected. LS means are from analysis of MMRM and the model includes treatment group, baseline value, visit and treatment-by-visit interaction

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percentage of body surface area
Mean Change From Baseline in Percent Body Surface Area (%BSA)
percentage of body surface areaIxekizumab Q2WIxekizumab Q4W
Mean Change From Baseline in Percent Body Surface Area (%BSA)-26.1 ± 1.39-28.0 ± 1.39
SecondaryMean Change From Baseline on the Psoriasis Area and Severity Index (PASI)

The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in PASI scores compared to baseline. LS means are from analysis of MMRM and the model includes treatment group, baseline value, visit and treatment-by-visit interaction.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline on the Psoriasis Area and Severity Index (PASI)
units on a scaleIxekizumab Q2WIxekizumab Q4W
Mean Change From Baseline on the Psoriasis Area and Severity Index (PASI)-22.00 ± 0.456-22.72 ± 0.456
SecondaryTime to at Least a 2 Point Improvement on the PatGA Score

The PatGA is a patient-administered single-item scale on which participants are asked to rank by selecting a number on a 0 to 5 NRS the severity of their psoriasis "today" from 0 (Clear) = no psoriasis to 5 (Severe) = the worst their psoriasis has ever been.

Time frame:
Baseline though Week 12
Reported as:
Median · Days
Time to at Least a 2 Point Improvement on the PatGA Score
DaysIxekizumab Q2WIxekizumab Q4W
Time to at Least a 2 Point Improvement on the PatGA Score10.0 (6.0 to 12.0)13.5 (5.0 to 22.0)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ixekizumab Q2W Induction Dosing Period—0/6 (0%)5/6 (83.3%)
Ixekizumab Q4W Induction Dosing Period—0/6 (0%)5/6 (83.3%)
Ixekizumab 80 mg Q4W Maintenance—0/12 (0%)9/12 (75%)
Ixekizumab 80 mg Q4W Post-treatment—0/12 (0%)1/12 (8.3%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventIxekizumab Q2W Induction Dosing PeriodIxekizumab Q4W Induction Dosing PeriodIxekizumab 80 mg Q4W MaintenanceIxekizumab 80 mg Q4W Post-treatment
Injection site urticariaGeneral disorders0/62/60/120/12
Upper respiratory tract infectionInfections and infestations0/61/64/120/12
Biopsy prostateInvestigations0/51/30/80/8
ArthralgiaMusculoskeletal and connective tissue disorders2/60/60/120/12
Injection site erythemaGeneral disorders1/61/61/120/12
HordeolumInfections and infestations0/61/60/120/12
InfluenzaInfections and infestations0/60/62/120/12
Localised infectionInfections and infestations1/60/60/120/12
Biopsy breastInvestigations0/60/62/120/12
AcneSkin and subcutaneous tissue disorders1/60/60/120/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ixekizumab Q2WIxekizumab Q4WTotal
Mean41.8 ± 12.5455.2 ± 7.3948.5 ± 12.03
Sex: Female, Male
Sex: Female, Male(Participants)Ixekizumab Q2WIxekizumab Q4WTotal
Female134
Male538
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ixekizumab Q2WIxekizumab Q4WTotal
Hispanic or Latino123
Not Hispanic or Latino549
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ixekizumab Q2WIxekizumab Q4WTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American112
White459
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Ixekizumab Q2WIxekizumab Q4WTotal
United States6612
08

Study locations

1 site
  • Mount Sinai School of Medicine Dermatology Clinical Trials
    New York, New York 10029, United States
09

References and documents

Publications

  • Khattri S, Goldblum O, Solotkin K, Amir Y, Min MS, Ridenour T, Yang FE, Lebwohl M. Early Onset of Clinical Improvement with Ixekizumab in a Randomized, Open-label Study of Patients with Moderate-to-severe Plaque Psoriasis. J Clin Aesthet Dermatol. 2018 May;11(5):33-37. Epub 2018 May 1. PubMed 29785237 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Sep 2015 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2015
First posted
Mar 13, 2015
Start
Apr 2015
Primary completionActual
Sep 2015
CompletionActual
Aug 2016
Results first posted
Oct 21, 2016
Last update
Sep 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02387801
Responsible party
Sponsor
First posted
Mar 13, 2015
Start date
Apr 2015
Primary completion
Sep 2015
Completion
Aug 2016
Results posted
Oct 21, 2016
Last update
Sep 18, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion